Publication | Closed Access

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Lymphoid NeoplasiaMedicineImmunologyPathologyAutoimmunityAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation OncologyCancer Research